During recent decades, substantial progress has been made in clinical strategies for treating hematological malignancies. Not only did China benefit from the global progression in the management of acute promyelocytic leukemia, risk-stratification-directed strategies for acute or chronic leukemia and haploidentical hematopoietic stem cell transplantation, the unique system developed by Chinese doctors has also become inspiration for refining global clinical practice. The multicenter trials and collaborations adhering to international standards might further strengthen the global impact and lead the way in specific fields of research worldwide. Hematological malignancies, including acute and chronic leukemia, lymphoma and multiple myeloma, constitute a series of critical life-threatening diseases, especially in children and adolescents [1]. During recent decades, substantial progress has been made in clinical strategies for treating hematological malignancies, which have shifted from "incurable" to "curable". In general, the 3-to 6-year disease-free survival (DFS) of hematological malignancies in comprehensive hematology centers in China reached 60%-70%, and in several diseases the 2-year DFS exceeded 95% [2][3][4][5][6][7][8]. In this process, Chinese patients benefited from the global developments of hematological malignancy therapy, not only with respect to therapeutic strategies but also with regard to the methodology in clinical trial design, standardization of clinical practice and multi-center cooperation. The innovations of Chinese doctors also prompted global progression, especially in managing acute promyelocytic leukemia (APL), risk-stratification-directed strategies for leukemia and haploidentical hematopoietic stem cell transplantation (Haplo-HSCT). The present review focuses on the unique anti-malignancy clinical strategies innovated by Chinese doctors and provides insight into their global impact.
Hematological malignancies, including acute and chronic leukemia, lymphoma and multiple myeloma, constitute a series of critical life-threatening diseases, especially in children and adolescents [1] . During recent decades, substantial progress has been made in clinical strategies for treating hematological malignancies, which have shifted from "incurable" to "curable". In general, the 3-to 6-year disease-free survival (DFS) of hematological malignancies in comprehensive hematology centers in China reached 60%-70%, and in several diseases the 2-year DFS exceeded 95% [2] [3] [4] [5] [6] [7] [8] . In this process, Chinese patients benefited from the global developments of hematological malignancy therapy, not only with respect to therapeutic strategies but also with regard to the methodology in clinical trial design, standardization of clinical practice and multi-center cooperation. The innovations of Chinese doctors also prompted global progression, especially in managing acute promyelocytic leukemia (APL), risk-stratification-directed strategies for leukemia and haploidentical hematopoietic stem cell transplantation (Haplo-HSCT). The present review focuses on the unique anti-malignancy clinical strategies innovated by Chinese doctors and provides insight into their global impact.
Acute promyelocytic leukemia (APL)
In the "chemotherapy era" with daunorubicin or earlier, APL was once a highly fatal malignancy because of a high incidence (approximately 30%) of early death caused by hemorrhage and so on, while the first complete remission rate (CR1) was less than 50% [9] [10] [11] . Chinese doctors had made special contributions by introducing targeted therapy including all-trans retinoic acid (ATRA) and arsenic acid for APL [12] . In the late 1980s, the Shanghai group [13, 14] first introduced ATRA into the clinics, and the CR1 rate reached 90% without increasing the risk of hemorrhage. These findings of ATRA were soon replicated in France and the USA, which advocated the application of ATRA in both induction and maintenance compared with the standard chemotherapy using daunorubicin and cytarabine [15, 16] . Because the therapeutic effects of ATRA were limited due to the high relapse rate in maintenance [17] , the introduction of arsenic acid from traditional Chinese medicine (in the form of arsenic trioxide or arsenic disulfide) by Harbin, Shanghai and Beijing further improved the clinical outcomes of APL, yielding the 3-to 6-year DFS of about 80%-90% [18] [19] [20] . Although arsenic trioxide (ATO) was discovered more than a decade before the discovery to ATRA, this unique system was underestimated or ignored outside of China until a series of clinical reports and mechanism studies were conducted at the molecular level according to international standards [21] [22] [23] [24] . Subsequently, ATRA plus ATO were gradually accepted as the first-line treatment over chemotherapy in the management of APL [25] [26] [27] [28] .
Therefore, modern biomedical approaches and welldesigned clinical trials play key roles in connecting the unique systems of China with those of the world. Realgar-Indigo naturalis formula (RIF) for APL is another concrete example. The formula is representative of traditional Chinese medicine, prescribing a combination of plant species and minerals based on clinical experience. Although the clinical efficacy of RIF has been proven in a single-arm clinical trial in the 1990s [29] , the international hematology community did not recognize the benefits of RIF because of the obscure mechanisms and the absence of strict trials. By dissecting the mode of action of RIF at the molecular, cellular, and organism levels, the Shanghai group [30] reported tetra-arsenic tetrasulfide as a principal component of RIF, whereas other adjuvant ingredients yielded synergy in targeting APL cells in vitro and in vivo. Recently, a prospective, multi-center, randomized, controlled study led by the Shanghai and Beijing groups proved that oral RIF achieved a high rate of remission and survival comparable with that of intravenous ATO as a front-line treatment for newly diagnosed APL, the 3-year overall survival rate (OS) was 99.1% (RIF) and 96.6% (ATO) ( Table 1 ) [5] . Later, in a single-arm study of non-high-risk patients by the Beijing group [31, 32] , oral RIF and ATRA were administered to patients in a largely home-based treatment protocol, promoting the new era to "Cure leukemia in out-patient department".
Despite the high incidence of CR and OS, resistance to arsenic acid resulted in a worse outcome. Amino acid substitutions of A216V and L218P in the promyelocytic leukemia protein (PML) B2 domain have been detected in patients clinically resistant to arsenic trioxide [33] , recently the Beijing group identified 4 new mutations in PML transcripts with A216T, S214L, L217F, and S220G, which suggested the presence of a PML mutational hot-spot domain (C212-S220). These mutations may be helpful in guiding risk-stratification-directed treatment choices in the a) APL, acute promyelocytic leukemia; RIF, Realgar-Indigo naturalis formula; ATRA, all-trans retinoic acid; RCT, randomized controlled trial; OS, overall survival rate; DFSAML, acute myeloid leukemia; HAA, homoharringtonine, cytarabine, aclarubicin; HAD, homoharringtonine, cytarabine, daunorubicin; DA, cytarabine, daunorubicin; EFS, event free survival; CIR, cumulative incidence of relapse; MRD, minimal residual disease; MMR, major molecular response; CML-CP, chronic myeloid leukemia in chronic phase; HID, haploidentical donor; ISD, HLA-identical sibling donor.
relapse APL and finding new strategies for overcoming arsenic acid resistance [34] . Because ATO can hardly penetrate the blood-brain-barrier, the management of extra medullary relapse of APL in the central nervous system (CNS) was difficult. The Harbin group [35] first demonstrated that neuron cells were more tolerant to ATO than leukemia cells in vitro, based on these findings, the co-infusion of ATO and mannitol was introduced to patients with CNS relapse, as comparable arsenic levels were achieved in the cerebrospinal fluid and plasma, these patients exhibited improved outcomes, with a 5-year OS at 82.4% [36] .
By incorporating modern molecular biotechnology into the discoveries of traditional Chinese medicine, fitting this unique system the international standards, Chinese doctors globally introduced a new era of therapeutic strategy for managing APL.
Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)
To manage AML and ALL, Chinese doctors made the following innovative contributions: the identification of genetic abnormalities; novel regimens for chemotherapy or targeted therapy; and development of risk-stratificationdirected therapy.
The Shanghai group [37] and several other centers in China pioneered the genetic analysis of acute leukemia worldwide. Using exome sequencing, the mutations of DNA-methyltransferase 3A (DNMT3A) in acute monocytic leukemia were found to be correlated with the alterations of DNA methylation patterns and gene expression profiles. In cohorts of thousands of patients with newly diagnosed ALL, it was revealed that Chinese ALL patients demonstrated more adverse prognostic factors, such as breakpoint cluster region-Abelson (BCR-ABL), than western patients [38, 39] . In AML, DNMT3A and mixed-lineage leukemia (MLL) mutations were associated with OS and DFS, whereas biallelic CCAAT/enhancer-binding protein alpha (CEBPA) or nucleophosmin1 (NPM1) mutations without DNMT3A mutations exhibited a better OS. Recently, using wholegenome sequencing, the Tianjin group [40, 41] suggested that point mutations in SET domain containing 2 (SETD2) were associated with multiple major chromosomal aberrations, such as H3K36 trimethylation, and promoted the self-renewal potential of leukemia stem cells. In addition to genetic mutations, the series of aberrantly expressed microRNA and distinct metabolism signatures were indicated as prognostic markers for acute leukemia [42] [43] [44] . Not only did these cytogenetic and molecular abnormalities provide prognostic value, they also yielded insight into the mechanisms of leukemogenesis and contributed to the potential endeavors to find new therapeutic strategies.
Homoharringtonine, derived from a natural plant alkaloid, has been widely used in China to treat patients with AML; however, its global impact has been limited as in the case of ATO. Recently, a multi-center, randomized, controlled trial in a large population from 17 institutions in China helped to solve this problem. Three induction regimens were assigned at a 1 : 1 : 1 ratio, which included HAA (homoharringtonine, cytarabine, aclarubicin), HAD (homoharringtonine, cytarabine, daunorubicin) and DA (cytarabine, daunorubicin). HAA was superior to DA, which was still the first-line treatment of induction therapy, with a superior CR rate of induction (73% vs. 61%, P=0.0108) and 3-year DFS (35.4% vs. 23.1%, P=0.0023) [45] . As a semisynthetic version of homoharringtonine, omacetaxinemepe succinate was recently approved by the Food and Drug Administration for the treatment of advanced leukemia; this unique agent with Chinese characters might play an increasing role in AML therapy and yield more influence on the guidelines dominated in the western world. Many candidate agents, such as oridonin, a diterpenoid extracted from medicinal herbs, targeting AML1-eight-twenty one oncoprotein (ETO) fusion protein and inhibiting the activity of c-Kit(+) leukemia-initiating cells in t(8;21) AML, might be a potential lead compound for the molecular target-based therapy of leukemia [46, 47] .
Although acute myeloid leukemia (AML) with t(8;21) generally has a favorable prognosis, relapse occurs in 40%-60% of the patients, and the long-term survival is unsatisfactory [48] . Therefore, the early identification of patients with high-risk relapse in chemotherapy might provide valuable information regarding the selection of more aggressive strategies, such as allogeneic hematopoietic stem cell transplantation (allo-HSCT) as post remission therapy. It has been demonstrated in a multicenter trial in China that the minimal residual disease (MRD) status after the second consolidation, rather than induction or first consolidation, could discriminate high-risk relapse patients. Allo-HSCT could reduce the incidence of relapse and improve the survival rate compared with chemotherapy for these high-risk patients (cumulative incidence of relapse/CIR, HSCT vs. chemotherapy: 22.1% vs. 78.9%, P<0.0001). Therefore, MRD-directed pre-transplant risk stratification may improve the outcome of t(8;21) AML in CR1 [49] . Furthermore, for those high-risk patients who received allo-HSCT, MRD within 3 months after HSCT, rather than c-KIT mutations, was suggested as an independent factor for CIR and DFS in another multi-center study [50] .
In sum, three aspects of the contributions by Chinese doctors could be integrated as "Prognostic genetic biomarkers-Regimens solutions-Risk-stratification-directed strategies," which are in accordance with the trends of "Precision Medicine" [51] .
Chronic myeloid leukemia (CML)
Chinese patients with CML benefited from the introduction of tyrosine kinase inhibitors (TKIs) [52, 53] . Because the innovations of new TKIs were monopolized by pharmaceutical industries in the western world, it is worth considering how to present "the voice from China" in this situation.
Allo-HSCT is no longer considered to be the first-line therapy for managing CML in the "TKI era" in developed countries. There is a shortage of evidence-based studies to address the optimization of therapeutic strategy for CML other than TKI. In prospective studies of China, imatinib results in comparable or better outcomes than an human leukocyte antigen (HLA)-identical sibling allo-HSCT as an initial therapy for CML-CP (chronic phase) [6], whereas allo-HSCT confers significant survival advantages for highand intermediate-risk patients with CML in AP (accelerated phase) or BC (blast crisis) compared with imatinib [7, 54] . These studies helped to refine the European Leukemia Net guidelines for CML [55] . As BCR-ABL transcripts level play a critical role in guiding therapeutic strategies, it would be impossible to directly compare these results between different laboratories in the absence of uniform standards, not to mention initiating a multi-center study. Rather than using the log reduction method, the molecular response evaluated by BCR-ABL (IS) can better differentiate patients and allows for a comparison among molecular response results from different laboratories [56] . Through international cooperation, Peking University's laboratory was first certified by the BCR-ABL (IS) international laboratory and led the standardization of BCR-ABL monitoring in 23 central laboratories throughout China [57] . Based on uniform molecular monitoring, the "CML Consortium of China" was established and multicenter studies achieved promising results [58] .
Haploidentical hematopoietic stem cell transplantation (Haplo-HSCT)
Allo-HSCT provides the powerful curative weapons for patients with the majority of hematological malignancies. Due to the "One Child Policy," there has been a shortage of HLA-identical siblings for Chinese patients who need HSCT, whereas only 11% could find matched unrelated donors in the total patients who tried to search for donors in "China Marrow Donor Program." Therefore, haplo-HSCT based on related family donors has a unique role in the treatment of hematologic diseases in China. Nevertheless, haplo-HSCT was once a dream because of the high incidence of rejection and severe graft-versus-host disease (GvHD) [59] .
Based on series of mechanism research on cytokines induced immune tolerance [60] [61] [62] [63] , Peking University researchers developed a novel approach for HLA-mismatched/ haploidentical myeloablative blood and marrow transplantation without in vitro T cell depletion within the last 10 years (Beijing Protocol) [8, 64] . Combinations of granulocyte colony-stimulating factor (G-CSF) and anti-thymocyte globulin (ATG) have been confirmed to play a key role in overcoming HLA barriers [65, 66] , probably by immune regulatory cells, such as Th17/Tc 17, Treg, and myeloid-derived suppressor cells (MDSCs) [67] [68] [69] [70] . In a prospective, randomized trial, it was suggested that 10 mg kg 1 ATG was superior to 6 mg kg 1 for lower grades III-IV acute GvHD [71] .
In several single-center studies, haplo-HSCT was found to have similar therapeutic effects compared to HSCT with HLA identical sibling donor (ISD) [72] or matched unrelated donor (URD) [73] , and may improve the outcomes of children compared with umbilical cord blood (UCB) transplantation [74] . Recently, in multi-center studies, haplo-HSCT exhibited a similar outcome as ISDs HSCT on adults with intermediate-or high-risk acute myeloid leukemia in CR1 [3] . Additionally, haplo-HSCT can achieve a desirable health-related quality of life (HRQoL) and a lower risk of late effects compared with ISD HSCT [75, 76] .
Haplo-HSCT is superior to chemotherapy as postremission treatment for intermediate-or high-risk AML or ALL in CR1. In a recent prospective study with intermediate-or high-risk AML, it was revealed that haplo-HSCT resulted in a lower cumulative incident of relapse (12.0% vs. 57.8%; P<0.0001) and superior 4-year DFS (73.1% vs. 44.2%; P<0.0001) compared with the chemotherapy-alone group [77] . Similar results were observed among high-and stand-risk Ph-negative ALL CR1 patients after haplo-HSCT[4] [78] .
As the new era in which "everyone has a donor" arrives [79] , there will be a shift from donor shortage to diversification. HLA plays a predominant role in selection of the best donor in unrelated transplants, nevertheless, it has not been significantly correlated with transplant outcomes in haplo-HSCT [80, 81] ; therefore, we might focus on factors other than HLA to determine the impact on transplant outcomes. Based on a large sample size and relative consistency of transplant variables, the Beijing group [82] proposed an algorithm other than HLA for donor selection. It was suggested that choosing young, male, non-inherited maternal antigens(NIMA)-mismatched donors is reasonable. The transplants from older mothers and non-inherited paternal antigens (NIPA)-mismatched donors should probably be avoided. Additionally, donor-specific anti-HLA antibodies (DSAs) were indicated to be associated with primary graft failure (GF), transplant-related mortality and inferior overall survival following haplo-HSCT [83] . Donor selection based on other non-HLA systems, such as donor inhibitory killer cell immunoglobulin-like receptors (KIRs), remain to be further elucidated [84] .
Since "Beijing Protocol" has been widely incorporated into clinical practice in most comprehensive HSCT centers of China, haplo-HSCT has become the largest donor source compared with ISD donors and take nearly 48% of total allo-HSCT cases in China (Figure 1) . "Beijing Protocol" was also replicated and conducted with promising results by Di Bartolomeo et al. [85] in Europe. As Handgretinger commented, "more than half of the HLA haplotype mismatched transplantations performed worldwide will follow similar protocols (Beijing Protocol) [86] .
The development of Haplo-HSCT in China has changed the current situation of the international HSCT system. More innovative and standard clinical systems like "Beijing Protocol" are needed to keep the global impact of China.
Conclusions and prospective
As one of the most dynamic fields in translational medicine and precision medicine, there are both opportunities and challenges to anti-hematological malignancies. Only could deep mechanism studies, well designed clinical trials and multicenter collaborations bring the unique system of China to the world, which might be adopted into international systems or standards, and contribute to the global progression in fighting against hematologic malignancy. 
